States Should Remove Barriers to Advanced Practice Registered Nurse Prescriptive Authority to Increase Access to Treatment for Opioid Use Disorder

Abstract

In October 2018, President Trump signed into law H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. This piece of legislation addresses treatment, prevention, recovery, and enforcement with particular attention to access in rural areas. It contains numerous provisions to improve needed access to treat substance use disorders and especially opioid use disorder (OUD), including mandatory coverage of medications for OUD, partial elimination of Medicaid payment for inpatient mental health treatment, and state planning grants to increase provider capacity. Many of these provisions would be significantly enhanced by removing barriers to prescriptive authority for Advanced Practice Registered Nurses (APRNs), including Nurse Practitioners, Clinical Nurse Specialists, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and other state-specific titles for nurses whose scope allows the prescription of controlled substances. This policy brief includes a history of the role of APRNs in the delivery of medications for OUD, scope of practice restrictions related to prescriptive authority as a barrier in their ability to deliver care for this vulnerable population, and actionable strategies that APRNs can take to advocate for an increased role in providing care.

Keywords

controlled substances nurse practitioners mental health opioid-related disorders advanced practice nursing

Get full access to this article

View all access options for this article.

References

AB-890 Nurse practitioners: Scope of practice: Practice without standardized procedures. (2020). https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=201920200AB890

Alexander

G. C.

Stoller

K. B.

Haffajee

R. L.

Saloner

(2020). An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19. Annals of Internal Medicine, 173(1), 57–58. https://doi.org/10.7326/m20-1141

Altarum. (2018). Economic toll of opioid crisis in U.S. exceeded $1 trillion since 2001. https://altarum.org/news/economic-toll-opioid-crisis-us-exceeded-1-trillion-2001

American Association of Nurse Practitioners. (2020a, November 4). COVID-19 state emergency response: Temporarily suspended and waived practice agreement requirements. https://www.aanp.org/advocacy/state/covid-19-state-emergency-response-temporarily-suspended-and-waived-practice-agreement-requirements

American Association of Nurse Practitioners. (2020b). Nurse practitioner prescriptive authority. https://www.aanp.org/advocacy/advocacy-resource/position-statements/nurse-practitioner-prescriptive-privilege

American Association of Nurse Practitioners. (2020c). NP fact sheet. https://www.aanp.org/about/all-about-nps/np-fact-sheet

Andrilla

C. H. A.

Coulthard

Patterson

D. G.

(2018). Prescribing practices of rural physicians waivered to prescribe buprenorphine. American Journal of Preventive Medicine, 54(6), S208–S214. https://doi.org/10.1016/j.amepre.2018.02.006

Andrilla

C. H. A.

Moore

T. E.

Patterson

D. G.

Larson

E. H.

(2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health, 35(1), 108–112. https://doi.org/10.1111/jrh.12307

Andrilla

C. H. A.

Patterson

D. G.

Garberson

L. A.

Coulthard

Larson

E. H.

(2018). Geographic variation in the supply of selected behavioral health providers. American Journal of Preventive Medicine, 54(6), S199–S207. https://doi.org/10.1016/j.amepre.2018.01.004

10.

Andrilla

C. H. A.

Patterson

D. G.

Moore

T. E.

Coulthard

Larson

E. H.

(2018). Projected contributions of nurse practitioners and physicians assistants to buprenorphine treatment services for opioid use disorder in rural areas. Medical Care Research and Review, 77(2), 208–216. https://doi.org/10.1177/1077558718793070

11.

Assembly Bill No. 890, 890, California Legislature. (2019). leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201920200AB890

12.

Barnes

Maier

C. B.

Altares Sarik

Germack

H. D.

Aiken

L. H.

McHugh

M. D.

(2017). Effects of regulation and payment policies on nurse practitioners’ clinical practices. Medical Care Research and Review, 74(4), 431–451. https://doi.org/10.1177/1077558716649109

13.

Barnes

Richards

M. R.

McHugh

M. D.

Martsolf

(2018). Rural and nonrural primary care physician practices increasingly rely on nurse practitioners. Health Affairs, 37(6), 908–914. https://doi.org/10.1377/hlthaff.2017.1158

14.

Barnett

Lee

D. C.

Frank

(2019). In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants. Health Affairs, 38(12), 2048–2056. https://doi.org/10.1377/hlthaff.2019.00859

15.

Buerhaus

P. I.

DesRoches

C. M.

Dittus

Donelan

(2015). Practice characteristics of primary care nurse practitioners and physicians. Nursing Outlook, 63(2), 144–153. https://doi.org/10.1016/j.outlook.2014.08.008

16.

Chapman

S. A.

Toretsky

Phoenix

B. J.

(2019). Enhancing psychiatric mental health nurse practitioner practice: Impact of state scope of practice regulations. Journal of Nursing Regulation, 10(1), 35–43. https://doi.org/10.1016/S2155-8256(19)30081-X

17.

Comer

S. D.

Sullivan

M. A.

Rothenberg

J. L.

Kleber

H. D.

Kampman

Dackis

O’Brien

C. P.

(2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. JAMA Psychiatry, 63(2), 210–218. https://doi.org/10.1001/archpsyc.63.2.210

18.

Comprehensive Addiction and Recovery Act of 2016, P.L. 114-198, 524 Stat. (2016).

19.

Connery

H. S.

(2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23(2), 63–75. https://doi.org/10.1097/hrp.0000000000000075

20.

Doernberg

Krawczyk

Agus

Fingerhood

(2019). Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis? Substance Abuse, 40(2), 148–153. https://doi.org/10.1080/08897077.2019.1572052

21.

Doescher

M. P.

Andrilla

C. H.

Skillman

S. M.

Morgan

Kaplan

(2014). The contribution of physicians, physician assistants, and nurse practitioners toward rural primary care: Findings from a 13-state survey. Medical Care, 52(6), 549–556. https://doi.org/10.1097/mlr.0000000000000135

22.

Fornili

Fogger

(2017). Nurse practitioner prescriptive authority for buprenorphine: From DATA 2000 to CARA 2016 Journal of Addictions Nursing, 28(1), 43–48. https://doi.org/10.1097/JAN.0000000000000160

23.

Gibson

Degenhardt

Mattick

R. P.

Ali

White

O'Brien

(2008). Exposure to opioid maintenance treatment reduces long-term mortality. Addiction, 103(3), 462–468. https://doi.org/10.1111/j.1360-0443.2007.02090.x

24.

Hancock

Mennenga

King

Andrilla

Larson

E. B.

Schou

(2017). Treating the rural opioid epidemic. https://www.ruralhealthweb.org/NRHA/media/Emerge_NRHA/Advocacy/Policy%20documents/Treating-the-Rural-Opioid-Epidemic_Feb-2017_NRHA-Policy-Paper.pdf

25.

Huhn

A. S.

Dunn

K. E.

(2017). Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment, 78, 1–7. https://doi.org/10.1016/j.jsat.2017.04.005

26.

Hussain

P. L.

(2020). Opioid use disorder education for student nurse practitioner. https://sigma.nursingrepository.org/handle/10755/20884

27.

Hutchinson

Catlin

Andrilla

C. H. A.

Baldwin

L. M.

Rosenblatt

R. A.

(2014). Barriers to primary care physicians prescribing buprenorphine. Annals of Family Medicine, 12(2), 128–133. https://doi.org/10.1370/afm.1595

28.

Institute of Medicine. (2011). Future of nursing: Leading change, advancing health. The National Academies Press. https://doi.org/10.17226/12956

29.

Johnson

R. E.

Jaffe

J. H.

Fudala

P. J.

(1992). A controlled trial of buprenorphine treatment for opioid dependence. JAMA, 267(20), 2750–2755. https://doi.org/10.1001/jama.1992.03480200058024

30.

Jones

McCance-Katz

(2019). Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction, 114(3), 471–482. https://doi.org/10.1111/add.14436

31.

Jones

C. M.

Campopiano

Baldwin

McCance-Katz

(2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health, 105(8), e55–e63. https://doi.org/10.2105/AJPH.2015.302664

32.

Klivans

(2019). Could expanding nurse’s scope of care help fight the opioid epidemic in California? https://www.kqed.org/news/11743543/could-expanding-nurses-scope-of-care-help-fight-the-opioid-epidemic-in-california

33.

Krupitsky

Nunes

E. V.

Ling

Illeperuma

Gastfriend

D. R.

Silverman

B. L.

(2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. The Lancet, 377(9776), 1506–1513. https://doi.org/10.1016/S0140-6736(11)60358-9

34.

Lewis

L. F.

Jarvis

(2019). Undergraduate nursing students' experiences and attitudes towards working with patients with opioid use disorder in the clinical setting: A qualitative content analysis. Nurse Education Today, 73, 17–22. https://doi.org/10.1016/j.nedt.2018.11.001

35.

Mack

K. A.

Jones

C. M.

Ballesteros

M. F.

(2017). Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas — United States. MMWR Surveillance Summaries 2017, 66(SS–19), 1–12. https://doi.org/10.15585/mmwr.ss6619a1

36.

Mahmoud

K. F.

Finnell

Lindsay

MacFarland

Marze

H. D.

Scolieri

B. B.

Mitchell

A. M.

(2019). Can screening, brief intervention, and referral to treatment education and clinical exposure affect nursing students' stigma perception toward alcohol and opioid use? Journal of the American Psychiatric Nurses Association, 25(6), 467–475. https://doi.org/10.1177/1078390318811570

37.

Maier

(2019, April 9). Many nurse practitioners cannot provide medications to treat opioid addiction. https://www.ucsf.edu/news/2019/04/413856/many-nurse-practitioners-cannot-provide-medications-treat-opioid-addiction

38.

Mattick

R. P.

Breen

Kimber

Davoli

(2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD002209.pub2

39.

Minozzi

Amato

Vecchi

Davoli

Kirchmayer

Verster

(2011). Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001333.pub3

40.

Modernization of the Professional Nursing Law, S.B. 25, Pennsylvania General Assembly. (2019). https://www.legis.state.pa.us/CFDOCS/Legis/PN/Public/btCheck.cfm?txtType=PDF&sessYr=2019&sessInd=0&billBody=S&billTyp=B&billNbr=0025&pn=0507

41.

Morgan

Everett

C. M.

Hing

(2014). Time spent with patients by physicians, nurse practitioners, and physician assistants in community health centers, 2006–2010. Healthcare, 2(4), 232–237. https://doi.org/10.1016/j.hjdsi.2014.09.009

42.

Muench

Spetz

Jura

Guo

Thomas

Perloff

(2019). Opioid-prescribing outcomes of Medicare beneficiaries managed by nurse practitioners and physicians. Medical Care, 57(6), 482–489. https://doi.org/10.1097/mlr.0000000000001126

43.

National Academies of Sciences Engineering and Medicine. (2019). Medications for opioid use disorder save lives. The National Academies Press. https://doi.org/10.17226/25310

44.

National Council of State Boards of Nursing. (2018). APRN consensus. https://www.ncsbn.org/5397.htm

45.

National Institute of Drug Abuse. (2020). Pennsylvania: Opioid-involved deaths and related harms. https://www.drugabuse.gov/opioid-summaries-by-state/pennsylvania-opioid-involved-deaths-related-harms

46.

Netherland

Botsko

Egan

J. E.

Saxon

A. J.

Cunningham

C. O.

Finkelstein

Gourevitch

M. N.

Renner

J. A.

Sohler

Sullivan

L. E.

Weiss

Fiellin

D. A.

(2009). Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment, 36(3), 244–251. https://doi.org/10.1016/j.jsat.2008.06.006

47.

Olsen

Sharfstein

J. M.

(2014). Confronting the stigma of opioid use disorder–and its treatment. JAMA, 311(14), 1393–1394. https://doi.org/10.1001/jama.2014.2147

48.

Padgett

T. M.

Barb

S. d.

Woolf

S. K.

Tielker

S. L.

(2020). Implementing an unfolding case study throughout the nursing curriculum to increase opioid addiction education. Journal of Nursing Education, 59(4), 235–238.

49.

Penn

(2019, June 25). It’s time to question the restrictions on buprenorphine. https://www.psychcongress.com/article/its-time-question-restrictions-buprenorphine

50.

Pew Charitable Trusts. (2019). Nurse licensing laws block treatment for opioid addiction. https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/04/21/nurse-licensing-laws-block-treatment-for-opioid-addiction

51.

Pierce

Bird

S. M.

Hickman

Marsden

Dunn

Jones

Millar

(2016). Impact of treatment for opioid dependence on fatal drug-related poisoning: A national cohort study in England. Addiction, 111(2), 298–308. https://doi.org/10.1111/add.13193

52.

Rex

S. A.

(2018, September 5). Pa. lawmakers should reject proposals to change nurse practitioner requirements. https://www.mcall.com/opinion/mc-opi-nurse-practitioner-legislation-20180905-story.html

53.

Ruhm

C. J.

(2017). Geographic variation in opioid and heroin involved drug poisoning mortality rates. American Journal of Preventive Medicine, 53(6), 745–753. https://doi.org/10.1016/j.amepre.2017.06.009

54.

Schuckit

M. A.

(2016). Treatment of opioid-use disorders. New England Journal of Medicine, 375(4), 357–368. https://doi.org/10.1056/NEJMra1604339

55.

Schwartz

R. P.

Gryczynski

O’Grady

K. E.

Sharfstein

J. M.

Warren

Olsen

Mitchell

S. G.

Jaffe

J. H.

(2013). Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. American Journal of Public Health, 103(5), 917–922. https://doi.org/10.2105/ajph.2012.301049

56.

Scope of Practice Policy. (2019). California scope of practice policy: State profile. http://scopeofpracticepolicy.org/states/ca/

57.

Spetz

Toretsky

Chapman

Phoenix

Tierney

(2019). Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA, 321(14), 1407–1408. https://doi.org/10.1001/jama.2019.0834

58.

Substance Abuse and Mental Health Services Administration. (2019a). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug use and Health (NSDUH Series H-54, Issue). https://www.samhsa.gov/data/

59.

Substance Abuse and Mental Health Services Administration. (2019b). Medication-assisted treatment of opioid use disorder. https://store.samhsa.gov/system/files/sma16-4892pg.pdf

60.

Substance Abuse and Mental Health Services Administration. (2020a). COVID-19 public health emergency response and 42 CFR part 2 guidance. https://www.samhsa.gov/sites/default/files/covid-19-42-cfr-part-2-guidance-03192020.pdf

61.

Substance Abuse and Mental Health Services Administration. (2020b). Opioid treatment program (OTP) guidance. https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf

62.

SUPPORT for Patients and Communities Act. (2018). https://www.congress.gov/bill/115th-congress/house-bill/6

63.

Thomas

C. P.

Fullerton

C. A.

Kim

Montejano

Lyman

D. R.

Dougherty

R. H.

Daniels

A. S.

Ghose

S. S.

Delphin-Rittmon

M. E.

(2014). Medication-assisted treatment with buprenorphine: Assessing the evidence. Psychiatric Services, 65(2), 158–170. https://doi.org/10.1176/appi.ps.201300256

64.

Tierney

Finnell

D. S.

Naegle

M. A.

LaBelle

Gordon

A. J.

(2015). Advanced practice nurses: Increasing access to opioid treatment by expanding the pool of qualified buprenorphine prescribers. Substance Abuse, 36(4), 389–392. https://doi.org/10.1080/08897077.2015.1101733

65.

University of Michigan Behavioral Health Workforce Research Center. (2018). Mapping supply of the U .S. psychiatric workforce. http://www.behavioralhealthworkforce.org/wp-content/uploads/2019/01/Y3-FA1-P2-Psych-Mapping-Full-Report-with-Appendix.pdf

66.

Vivolo-Kantor

A. M.

Seth

Gladden

R. M.

Mattson

C. L.

Baldwin

G. T.

Kite-Powell

Coletta

M. A.

(2018). Vital signs: Trends in emergency department visits for suspected opioid overdoses - United States, July 2016-september 2017. Morbidity and Mortality Weekly Report, 67(9), 279–285. https://doi.org/10.15585/mmwr.mm6709e1

67.

Walley

A. Y.

Alperen

J. K.

Cheng

D. M.

Botticelli

Castro-Donlan

Samet

J. H.

Alford

D. P.

(2008). Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Internal Medicine, 23(9), 1393–1398. https://doi.org/10.1007/s11606-008-0686-x

68.

Xue

Kannan

Greener

Smith

J. A.

Brasch

Johnson

B. A.

Spetz

(2018). Full scope-of-practice regulation is associated with higher supply of nurse practitioners in rural and primary care health professional shortage counties. Journal of Nursing Regulation, 8(4), 5–13. https://doi.org/10.1016/S2155-8256(17)30176-X